Total Funding
65
Total FundingSeed raised
Growth Score
pts
Heat Score
-1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
Pharmaceutical Company
- David Blum: CTO
- Yair Alerganti: Chief RA
About the Company
Q2pharma specializes in developing small-molecule drugs against multi-drug resistant (MDR) bacteria to be used as adjuvant medication with commonly used antibiotics or a standalone medication.
Our lead compound, F19 has shown promise in combating deadly MDR bacterial infections. Whereas antibiotics kill bacteria, as an antivirulent, F19 inhibits
bacterial toxin release, allowing the immune system to do its job more effectively. F19 has been shown to potentiate antibiotic efficacy, even to antibiotics that the pathogen is otherwise resistant. Recent experiments have demonstrated F19s potent effects on several of the most common and deadly MDR bacteria.
